Tirzepatide is a dual GIP and GLP-1 receptor agonist. Where semaglutide works on one receptor, tirzepatide engages two, each tied to a hormone involved in fullness and blood sugar control. Bodi Envi's Personalized Compounded Tirzepatide Weight-Management Programs, offered to people in the Houston metro, are built around it.
In a compounded program, a licensed compounding pharmacy prepares the medication for a specific patient after a licensed provider has written the prescription. The provider sets the weekly injection schedule, picks the starting dose and decides whether and when it changes.
Personalized Compounded Tirzepatide is not FDA-approved and is not equivalent to the FDA-approved products that contain the same active ingredient, Mounjaro® and Zepbound®. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, which is why a licensed provider decides case by case whether treatment is appropriate. Brand names are trademarks of their respective owners. Compounding pharmacies are regulated by state boards of pharmacy for sterile compounding and are required to follow United States Pharmacopeia standards.